National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 10 of 2003)

Overview

The National Health Act 1953 was enacted to establish and maintain a framework for the provision of health services in Australia, including the administration of the Pharmaceutical Benefits Scheme (PBS). This legislation was introduced to address the need for a structured approach to ensuring that Australians have access to affordable and necessary medications. The Act was enacted by the Parliament of Australia with the policy objective of providing equitable access to quality health services and pharmaceutical benefits. The Pharmaceutical Benefits Declaration under subsection 85(2AA), made in 2003 by Joan Corbett, Assistant Secretary of the Pharmaceutical Benefits Branch in the Department of Health and Ageing, specifies that certain drugs and medicinal preparations would no longer be covered under Part VII of the National Health Act 1953, effectively removing them from the PBS. This legislative instrument highlights the ongoing adjustments to the PBS to ensure it meets the evolving health needs of the population.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule, which in this instance includes Erythromycin Stearate. This legislation is enacted at the Commonwealth level, governing the scope of the Pharmaceutical Benefits Scheme, which is a key component of Australia's national healthcare system. The Declaration is effective from 1 August 2003 and specifies that the named drugs will cease to be covered under Part VII of the National Health Act 1953. This means that the specified drugs will no longer be eligible for benefits under the Pharmaceutical Benefits Scheme, impacting the availability and subsidies provided to patients. The Declaration is made by Joan Corbett, who is the Assistant Secretary of the Pharmaceutical Benefits Branch and the Delegate of the Minister for Health and Ageing, following advice from the Pharmaceutical Benefits Advisory Committee. The exclusion of these drugs from the scheme is intended to align with broader healthcare policy decisions regarding the cost and availability of pharmaceutical products in Australia.

Key Provisions

The key provisions of this legislative instrument (F2007B01098) relate to a declaration under subsection 85(2AA) of the National Health Act 1953. Joan Corbett, as the Assistant Secretary of the Pharmaceutical Benefits Branch and the Delegate of the Minister for Health and Ageing, has made a declaration effective from 1 August 2003, that the drugs and medicinal preparations listed in the attached schedule will cease to be covered by Part VII of the National Health Act 1953. This effectively means that the specified drugs and preparations, in this instance Erythromycin Stearate, will no longer be eligible for the benefits provided under the Pharmaceutical Benefits Scheme (PBS). Under this Act, certain obligations and requirements are imposed on the parties involved. Joan Corbett, as the Delegate, must obtain advice from the Pharmaceutical Benefits Advisory Committee, as required by subsection 85(2AB) of the National Health Act 1953, before making such a declaration. This ensures that the decision to delist a drug or medicinal preparation is informed by expert advice and evidence-based recommendations. The Pharmaceutical Benefits Advisory Committee plays a crucial role in providing expert advice on the clinical efficacy, safety, and cost-effectiveness of drugs and preparations, which is essential for making informed decisions regarding their eligibility for PBS coverage. Failure to comply with the provisions of this Act may result in both civil and criminal consequences. While the specific offences and penalties are not outlined in the text provided, it is important to note that breaches of the National Health Act 1953 may lead to legal action, fines, and other civil or criminal penalties. The maximum penalties for offences under the Act can vary depending on the specific provisions that have been breached and the severity of the offence. In general, penalties may include fines, imprisonment, or both, depending on the nature and extent of the breach. It is essential for all parties involved to be aware of their obligations under the Act and to take appropriate steps to ensure compliance with its provisions.